Factors affecting dialysis duration in children with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome

被引:0
|
作者
Khalid, Myda [1 ]
Miller, Chloe [1 ]
Gebregziabher, Netsanet [2 ]
Guckien, Zoe [1 ]
Goswami, Shrea [1 ]
Perkins, Anthony [2 ]
Andreoli, Sharon Phillips [1 ]
机构
[1] Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Biostat & Hlth Data Sci, Indianapolis, IN USA
关键词
Shiga toxin-producing Escherichia coli; Hemolytic uremic syndrome; Children; Dialysis; STEC-HUS; NSAID; Hematocrit; White blood cell count; Platelet count; PLATELET TRANSFUSIONS; DIARRHEA; INVOLVEMENT; NEUTROPHILS; PREDICTORS; STRICTURE; HYDRATION; OUTCOMES; RISK;
D O I
10.1007/s00467-022-05839-0
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Predicting disease severity can be informative for management of HUS. Dialysis requirement, volume depletion, elevated white blood cell counts, very young age, and use of antimotility agents are known factors associated with severe HUS.Methods A retrospective cohort analysis was performed to identify factors associated with dialysis duration using electronic medical record and chart review of 76 children <= 18 years of age at presentation with STEC-HUS identified through billing data from July 2008 to April 2020 at James Whitcomb Riley Hospital for Children, Indiana University, Indiana.Results Novel findings associated with prolonged dialysis duration were age >= 6 years old at presentation (p = 0.041) and lack of drop in platelets below 60,000/mm(3) anytime during the illness (p = 0.015). In addition, children with NSAID exposure trended longer on dialysis: 15 days with vs. 10 days without (p = 0.117). Known risk factors for severe disease including elevated peak white blood cell (WBC) count and higher hematocrit at presentation were also associated with longer dialysis duration: children with peak WBC > 20,000/mm(3) were on dialysis for 15 vs. 9.5 days (p = 0.002) and in children on dialysis <= 14 days hematocrit at presentation was 29.6% vs. 24.2% (p = 0.03). Children requiring dialysis for 20 days or longer were more likely to be on anti-hypertensive medications (p = 0.025) and have chronic kidney disease at 12-month follow up (p = 0.044).Conclusions Age >= 6, elevated WBC count > 20,000/mm(3), higher hematocrit at presentation, lack of drop in platelets to < 60,000/mm(3), and possibly NSAID exposure during illness are associated with longer dialysis duration in STEC-HUS.
引用
收藏
页码:2753 / 2761
页数:9
相关论文
共 50 条
  • [31] Investigation of enteropathogenic Escherichia coli and Shiga toxin-producing Escherichia coli associated with hemolytic uremic syndrome in Izmir Province, Turkey
    Bozcal, Elif
    Yigitturk, Gurkan
    Uzel, Atac
    Aydemir, Sabire Sohret
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2016, 46 (03) : 733 - 741
  • [32] A case of hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli after pericardiectomy
    Tome, June
    Maselli, Daniel Barry
    Im, Roeun
    Amdahl, Matthew Brian
    Pfeifle, Daniel
    Hagen, Catherine
    Halland, Magnus
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2022, 15 (01) : 123 - 127
  • [33] Blinded by Shiga Toxin-Producing O104 Escherichia coli and Hemolytic Uremic Syndrome
    Loudon, Sjoukje E.
    Dorresteijn, Eiske M.
    Catsman-Berrevoets, Coriene E.
    Verdijk, Rob M.
    Simonsz, Huibert J.
    Jansen, A. J. Gerard
    JOURNAL OF PEDIATRICS, 2014, 165 (02): : 410 - U258
  • [34] Diarrhea-negative hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli
    Balestracci, Alejandro
    Alconcher, Laura F.
    PEDIATRIC NEPHROLOGY, 2024, 39 (02) : 637 - 638
  • [35] A case of hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli after pericardiectomy
    June Tome
    Daniel Barry Maselli
    Roeun Im
    Matthew Brian Amdahl
    Daniel Pfeifle
    Catherine Hagen
    Magnus Halland
    Clinical Journal of Gastroenterology, 2022, 15 : 123 - 127
  • [36] Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000
    Tozzi, AE
    Caprioli, A
    Minelli, F
    Gianviti, A
    De Petris, L
    Edefonti, A
    Montini, G
    Ferretti, A
    De Palo, T
    Gaido, M
    Rizzoni, G
    EMERGING INFECTIOUS DISEASES, 2003, 9 (01) : 106 - 108
  • [37] A novel prognostic index in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli
    Loos, Sebastian
    PEDIATRIC NEPHROLOGY, 2022, 37 (02) : 465 - 465
  • [38] Dynamic Gene Network Analysis of Caco-2 Cell Response to Shiga Toxin-Producing Escherichia coli-Associated Hemolytic-Uremic Syndrome
    Bando, Silvia Y.
    Iamashita, Priscila
    Silva, Filipi N.
    Costa, Luciano da F.
    Abe, Cecilia M.
    Bertonha, Fernanda B.
    Guth, Beatriz E. C.
    Fujita, Andre
    Moreira-Filho, Carlos A.
    MICROORGANISMS, 2019, 7 (07)
  • [39] Comparison of Shiga toxin production by hemolytic-uremic syndrome-associated and bovine-associated Shiga toxin-producing Escherichia coli isolates
    Ritchie, JM
    Wagner, PL
    Acheson, DWK
    Waldor, MK
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2003, 69 (02) : 1059 - 1066
  • [40] Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children
    McKee, Ryan S.
    Schnadower, David
    Tarr, Phillip, I
    Xie, Jianling
    Finkelstein, Yaron
    Desai, Neil
    Lane, Roni D.
    Bergmann, Kelly R.
    Kaplan, Ron L.
    Hariharan, Selena
    Cruz, Andrea T.
    Cohen, Daniel M.
    Dixon, Andrew
    Ramgopal, Sriram
    Rominger, Annie
    Powell, Elizabeth C.
    Kilgar, Jennifer
    Michelson, Kenneth A.
    Beer, Darcy
    Bitzan, Martin
    Pruitt, Christopher M.
    Yen, Kenneth
    Meckler, Garth D.
    Plint, Amy C.
    Bradin, Stuart
    Abramo, Thomas J.
    Gouin, Serge
    Kam, April J.
    Schuh, Abigail
    Balamuth, Fran
    Hunley, Tracy E.
    Kanegaye, John T.
    Jones, Nicholas E.
    Avva, Usha
    Porter, Robert
    Fein, Daniel M.
    Louie, Jeffrey P.
    Freedman, Stephen B.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (08) : 1643 - 1651